Attached files
| file | filename |
|---|---|
| EX-5.1 - EX-5.1 - Timber Pharmaceuticals, Inc. | a2233829zex-5_1.htm |
| EX-4.21 - EX-4.21 - Timber Pharmaceuticals, Inc. | a2233829zex-4_21.htm |
| EX-4.20 - EX-4.20 - Timber Pharmaceuticals, Inc. | a2233829zex-4_20.htm |
| EX-4.19 - EX-4.19 - Timber Pharmaceuticals, Inc. | a2233829zex-4_19.htm |
| EX-4.18 - EX-4.18 - Timber Pharmaceuticals, Inc. | a2233829zex-4_18.htm |
| EX-1.1 - EX-1.1 - Timber Pharmaceuticals, Inc. | a2233829zex-1_1.htm |
| S-1/A - S-1/A - Timber Pharmaceuticals, Inc. | a2233829zs-1a.htm |
QuickLinks -- Click here to rapidly navigate through this document
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in this Amendment No. 2 to the Registration Statement on Form S-1 of our report (which contains an explanatory paragraph relating to the Company's ability to continue as a going concern as described in Note 2 to the consolidated financial statements) dated April 21, 2017, relating to the consolidated financial statements of BioPharmX Corporation, which appears in the Annual Report on Form 10-K of BioPharmX Corporation for the year ended January 31, 2017. We also consent to the reference of our firm under the heading "Experts" in such Registration Statement.
/s/ BPM LLP
San Jose, California
November 16, 2017
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM